Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Finance

Rapport Therapeutics gets $150 million in series B raise

by Laura Howes
August 31, 2023 | A version of this story appeared in Volume 101, Issue 29

 

Rapport Therapeutics has raised $150 million in series B funding—less than 6 months after its launch and successful series A fundraising. The precision neuroscience firm uses its platform to target receptor-associated proteins that are often more region specific than the receptors they link up to. Rapport has ongoing clinical programs in seizure and psychiatric disorders, and it says the cash will support this work.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.